MedTrace Logo

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

NCT00345540 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

Conditions

Interventions

DRUG

NOV-002

60 mg / mL / day / 20-23 Days

DRUG

Carboplatin

AUC 5 following IV bolus administration of NOV-002

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Cellectar Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Carolyn Kransner, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345540 on ClinicalTrials.gov